Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign.
Recommended Citation
Friedlander DF, von Landenberg N, Löppenberg B, Noldus J, Lipsitz SR, Cole AP, Abdollah F, Nguyen P, Choueiri T, Kibel AS, Trinh Q. Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign.. The Journal of urology 2019; .
Document Type
Article
Publication Date
1-16-2019
Publication Title
The Journal of urology
Abstract
PURPOSE: We sought to identify facility level variation in the use of definitive therapy among men diagnosed with clinically localized, low risk prostate cancer who were more than 65 years old and had a limited life expectancy of less than 10 years.
MATERIALS AND METHODS: Using data from the NCDB (National Cancer Database) we identified 18,178 men older than 65 years with less than 10-year life expectancy receiving definitive therapy at a total of 1,172 facilities for biopsy confirmed localized, low risk prostate cancer diagnosed between January 2004 and December 2013. A multilevel, hierarchical, mixed effects logistic regression model was fitted to predict the odds of receiving definitive therapy.
RESULTS: Overall 18,178 men (76%) older than 65 years with limited life expectancy and a diagnosis of low risk prostate cancer received definitive therapy, although the rate of therapy decreased significantly with time (p
CONCLUSIONS: We found significant facility level variation in rates of definitive therapy in men with localized prostate cancer and limited life expectancy. Health care providers and policy makers alike should be aware of the varying frequency with which this potentially low value service is performed.
PubMed ID
30633112
ePublication
ePub ahead of print
